Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump

Johnson & Johnson reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations.
Sales in the company’s pharmaceutical and medical devices businesses surged.
For full year 2024, J&J is forecasting sales of $87.8 billion to $88.6 billion and adjusted earnings of $10.55 to $10.75 per share.